Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps

This phase 3, double-blind randomized trial assessed the efficacy and safety of tezepelumab a thymic stromal lymphopoietin (TSLP) inhibitor in 408 adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps. Participants received standard care plus either tezepelumab or placebo for 52 weeks. Tezepelumab significantly improved all primary and key secondary outcomes, including reductions in total nasal-polyp and nasal-congestion scores, loss of smell, SNOT-22 total score, and Lund-Mackay score. The need for nasal-polyp surgery and systemic glucocorticoids was markedly reduced in the tezepelumab group. Adverse events were comparable between groups. The study supports tezepelumab as a promising biologic therapy for patients with refractory nasal polyps

This phase 3, double-blind randomized trial assessed the efficacy and safety of tezepelumab a thymic stromal lymphopoietin (TSLP) inhibitor in 408 adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps. Participants received standard care plus either tezepelumab or placebo for 52 weeks. Tezepelumab significantly improved all primary and key secondary outcomes, including reductions in total nasal-polyp and nasal-congestion scores, loss of smell, SNOT-22 total score, and Lund-Mackay score. The need for nasal-polyp surgery and systemic glucocorticoids was markedly reduced in the tezepelumab group. Adverse events were comparable between groups. The study supports tezepelumab as a promising biologic therapy for patients with refractory nasal polyps